Moderna (MRNA) Misses Q3 EPS by $1.35, Revenue Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Moderna (MRNA) Shares Plunge 13% on EPS and Revenue Miss and Slashed Covid-19 Vaccine Sales Guidance
November 4, 2021 8:31 AM EDTShares of Moderna (NASDAQ: MRNA) are down more than 13% in pre-open Thursday after the company delivered disappointing Q3 results and guidance.
Moderna reported Q3 EPS of $7.70, a handy miss compared to the analyst estimate of $9.05. Revenue for the quarter came in at $5 billion versus the consensus estimate of $6.21 billion.
Shares were further hit by the... More
